DOCSLIB.ORG

Rapid Phenotyping of Knockout Mice to Identify Genetic Determinants of Bone Strength

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Rapid Phenotyping of Knockout Mice to Identify Genetic Determinants of Bone Strength 231 1 B FREUDENTHAL and others Rapid skeletal phenotyping of 231:1 R31–R46 Review knockout mice Open Access Rapid phenotyping of knockout mice to identify genetic determinants of bone strength Correspondence should be addressed Bernard Freudenthal1, John Logan1, Sanger Institute Mouse Pipelines2, to J H D Bassett or Peter I Croucher3, Graham R Williams1 and J H Duncan Bassett1 G R Williams Email 1Molecular Endocrinology Laboratory, Department of Medicine, Imperial College London, London, UK [email protected] or 2Mouse Pipelines, Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge, UK graham.williams@imperial. 3Garvan Institute of Medical Research, Sydney, New South Wales, Australia ac.uk Abstract The genetic determinants of osteoporosis remain poorly understood, and there is a Key Words large unmet need for new treatments in our ageing society. Thus, new approaches f osteoporosis for gene discovery in skeletal disease are required to complement the current f bone genome-wide association studies in human populations. The International Knockout f genetics Mouse Consortium (IKMC) and the International Mouse Phenotyping Consortium (IMPC) f gene discovery provide such an opportunity. The IKMC generates knockout mice representing each of Endocrinology of the known protein-coding genes in C57BL/6 mice and, as part of the IMPC initiative, the Origins of Bone and Cartilage Disease project identifies mutants with significant outlier skeletal phenotypes. This initiative will add value to data from large human cohorts and Journal provide a new understanding of bone and cartilage pathophysiology, ultimately leading to the identification of novel drug targets for the treatment of skeletal disease. Journal of Endocrinology (2016) 231, R31–R46 Introduction A novel strategy for osteoporosis gene discovery whose aim is to disrupt each of the protein-coding genes in C57BL/6 mice, and the International Mouse Studies of human monogenic extreme phenotype Phenotyping Consortium (IMPC) that has established disorders have been instrumental in discovering a multidisciplinary and broad primary phenotype genetic and molecular mechanisms of common screen to characterise these mutant mice. By using diseases including obesity and diabetes (Yamagata et al. 1996, Montague et al. 1997). However, collection of samples from mice that have undergone the IMPC human extreme phenotype cohorts takes many years phenotyping pipeline, a bespoke rapid-throughput and requires significant effort and financial resource. multi-parameter skeletal phenotyping platform has A new approach to osteoporosis gene discovery been applied systematically to detect significant involves systematic identification of extreme skeletal phenotypes by screening minimal number of samples. phenotypes in mutant mouse lines that carry single- This phenotyping programme exploits the excellent gene knockouts representing all the known protein- replication of human skeletal disease in mice, and novel coding genes. This approach has been made possible by susceptibility genes can be validated by interrogating the International Knockout Mouse Consortium (IKMC), human osteoporosis cohorts. http://joe.endocrinology-journals.org © 2016 The authors This work is licensed under a Creative Commons DOI: 10.1530/JOE-16-0258 Published by Bioscientifica Ltd. Attribution 3.0 Unported License. Printed in Great Britain Downloaded from Bioscientifica.com at 10/03/2021 01:52:08AM via free access 10.1530/JOE-16-0258 Review B FREUDENTHAL and others Rapid skeletal phenotyping of 231:1 R32 knockout mice ‘Known unknowns’ in osteoporosis regulate the function of osteoblasts and osteoclasts. Both these pathways have subsequently been targeted by novel Osteoporosis is a worldwide healthcare problem that osteoporosis treatments. causes up to 9 million fractures annually (Johnell & Kanis The canonical Wnt/β-catenin signalling pathway 2006). Within the EU, it is estimated that osteoporosis is the key regulator of osteoblasts, which mediate bone affects 30 million people and osteoporotic fractures formation (Balemans et al. 2001, Gong et al. 2001, Boyden cost €37 billion annually (Hernlund et al. 2013). These et al. 2002, Little et al. 2002, Glass et al. 2005). The major numbers are projected to rise with the increasing elderly Wnt antagonist sclerostin (SOST) was first identified by population. Osteoporotic hip fractures are associated studying subjects with high bone mass due to sclerosteosis with a significant rise in mortality Sattui( & Saag 2014), and Van Buchem disease (Balemans et al. 2001, Brunkow especially during the year following fracture when it is et al. 2001). The importance of Wnt signalling was further estimated to be 8–36% (Abrahamsen et al. 2009). highlighted by the discovery of activating and inactivating The most important risk factors for osteoporotic mutations of the Wnt co-receptor LRP5, which results fracture are low bone mineral density (BMD) (clinically in high and low bone mass, respectively (Johnson et al. assessed by dual-energy X-ray absorptiometry (DEXA or 1997, Little et al. 2002). DXA)), increasing age and history of fracture (Johnell The RANK-RANKL-OPG pathway regulates osteoclasts, et al. 2005). There are two key determinants of adult which mediate bone resorption. This signalling pathway BMD: the peak bone mass attained in early adulthood was discovered in a functional screen of tumour necrosis and the rate of bone loss during ageing. Variation in BMD factor (TNF)/TNF receptor superfamily members. OPG has a large heritable genetic component. This is known is an endogenous inhibiting decoy receptor of RANKL from observations of familial clustering of osteoporosis related to the TNF receptor. In vivo overexpression of (Seeman et al. 1989, Keen et al. 1999) and from twin studies OPG in mice was found to cause osteopetrosis due to that have calculated that the heritable contribution lies impairment of the later stages of osteoclast differentiation between 40 and 90% (Mitchell & Yerges-Armstrong 2011). (Simonet et al. 1997). Subsequently, human osteopetrosis The heritable contribution to variance in BMD is greatest Endocrinology phenotypes with increased BMD were found to be caused in early adulthood (Gueguen et al. 1995), yet variation in of by mutations of RANK, RANKL and other related genes the rate of bone loss per se is also genetically determined involved in osteoclast differentiation (Coudert et al. 2015). (Kelly et al. 1993). Thus, genetic mechanisms contribute Journal significantly to the risk of osteoporosis. Nevertheless, the known BMD-associated genetic variants account for only Regulatory mechanisms in bone turnover 5.8% of the total variance (Estrada et al. 2012), indicating Knowledge of the signalling pathways that regulate that the majority of susceptibility genes have yet to bone turnover is essential for understanding the be identified. pathophysiology of osteoporosis. The manifest complexity of the signalling pathways and networks that regulate the cellular processes involved in dynamic bone turnover is Gene discovery from skeletal extreme phenotypes significant as small differences in function of individual Intrinsic and extrinsic factors, systemic hormones, components, including those not yet discovered, may neuronal innovation and mineral homeostasis can all have a combined effect on heritable risk of osteoporosis. affect bone mass. Significantly, many of the genes and The opposing processes of bone resorption and formation signalling pathways involved in the intrinsic regulation are tightly regulated by critical mechanisms including the of bone turnover and bone mass have been identified Wnt signalling and RANKL/RANK/OPG pathways (Fig. 1). by the study of human monogenic disorders associated At the cellular level, bone remodelling takes place in with extremes of BMD (Table 1). In traditional gene multicellular units, which comprise co-located osteoclasts discovery, the loci of causative alleles would be identified and osteoblasts within a bone remodelling cavity (Raggatt by linkage analysis in the families of index cases, followed & Partridge 2010). The bone remodelling cycle is initiated by positional cloning of the relevant genes (Alonso & by osteocytes in response to altered mechanical loading Ralston 2014). Such studies have identified the two (Nakashima et al. 2011), local microdamage and systemic key regulatory pathways – canonical Wnt signalling factors such as parathyroid hormone (Goldring 2015). and receptor activator of nuclear factor kappa-B ligand Unloading stimulates expression of RANKL and the Wnt (RANKL)/RANK/osteoprotegerin (OPG) that respectively inhibitors sclerostin and Dickkopf-related protein 1 (DKK-1) http://joe.endocrinology-journals.org © 2016 Society for Endocrinology Published by Bioscientifica Ltd. DOI: 10.1530/JOE-16-0258 Printed in Great Britain Downloaded from Bioscientifica.com at 10/03/2021 01:52:08AM via free access Review B FREUDENTHAL and others Rapid skeletal phenotyping of 231:1 R33 knockout mice Table 1 Monogenic disorders that have identified key skeletal genes in bone remodelling. Disease Clinical features Gene Mechanism Reference Reduced Osteoporosis- Reduced bone mass LRP5 Loss-of-function (Gong et al. 2001) bone mass pseudoglioma and blindness mutations disrupt Wnt syndrome (OPPGS) signalling and reduce osteoblastic bone formation. Osteogenesis Increased bone COL1A1, COL1A2, Loss-of-function (Baldridge et al. 2008; imperfecta fragility; blue sclerae CRTAP, LEPRE, mutations in collagen Sykes
Load more

Recommended publications
  • Rule Mining on Microrna Expression Profiles For
    Faculty of Engineering and Information Technology University of Technology, Sydney Rule Mining on MicroRNA Expression Profiles for Human Disease Understanding A thesis submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy by Renhua Song July 2016 CERTIFICATE OF AUTHORSHIP/ORIGINALITY I certify that the work in this thesis has not previously been submitted for a degree nor has it been submitted as part of requirements for a degree except as fully acknowledged within the text. I also certify that the thesis has been written by me. Any help that I have received in my research work and the preparation of the thesis itself has been acknowledged. In addition, I certify that all information sources and literature used are indicated in the thesis. Signature of Candidate i Acknowledgments First, and foremost, I would like to express my gratitude to my chief supervisor, Assoc. Prof. Jinyan Li, and to my co-supervisors Assoc. Prof. Paul Kennedy and Assoc. Prof. Daniel Catchpoole. I am extremely grateful for all the advice and guidance so unselfishly given to me over the last three and half years by these three distinguished academics. This research would not have been possible without their high order supervision, support, assistance and leadership. The wonderful support and assistance provided by many people during this research is very much appreciated by me and my family. I am very grateful for the help that I received from all of these people but there are some special individuals that I must thank by name. A very sincere thank you is definitely owed to my loving husband Jing Liu, not only for his tremendous support during the last three and half years, but also his unfailing and often sorely tested patience.
    [Show full text]
  • Whole Exome Sequencing in Families at High Risk for Hodgkin Lymphoma: Identification of a Predisposing Mutation in the KDR Gene
    Hodgkin Lymphoma SUPPLEMENTARY APPENDIX Whole exome sequencing in families at high risk for Hodgkin lymphoma: identification of a predisposing mutation in the KDR gene Melissa Rotunno, 1 Mary L. McMaster, 1 Joseph Boland, 2 Sara Bass, 2 Xijun Zhang, 2 Laurie Burdett, 2 Belynda Hicks, 2 Sarangan Ravichandran, 3 Brian T. Luke, 3 Meredith Yeager, 2 Laura Fontaine, 4 Paula L. Hyland, 1 Alisa M. Goldstein, 1 NCI DCEG Cancer Sequencing Working Group, NCI DCEG Cancer Genomics Research Laboratory, Stephen J. Chanock, 5 Neil E. Caporaso, 1 Margaret A. Tucker, 6 and Lynn R. Goldin 1 1Genetic Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, MD; 2Cancer Genomics Research Laboratory, Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, MD; 3Ad - vanced Biomedical Computing Center, Leidos Biomedical Research Inc.; Frederick National Laboratory for Cancer Research, Frederick, MD; 4Westat, Inc., Rockville MD; 5Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, MD; and 6Human Genetics Program, Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, MD, USA ©2016 Ferrata Storti Foundation. This is an open-access paper. doi:10.3324/haematol.2015.135475 Received: August 19, 2015. Accepted: January 7, 2016. Pre-published: June 13, 2016. Correspondence: [email protected] Supplemental Author Information: NCI DCEG Cancer Sequencing Working Group: Mark H. Greene, Allan Hildesheim, Nan Hu, Maria Theresa Landi, Jennifer Loud, Phuong Mai, Lisa Mirabello, Lindsay Morton, Dilys Parry, Anand Pathak, Douglas R. Stewart, Philip R. Taylor, Geoffrey S. Tobias, Xiaohong R. Yang, Guoqin Yu NCI DCEG Cancer Genomics Research Laboratory: Salma Chowdhury, Michael Cullen, Casey Dagnall, Herbert Higson, Amy A.
    [Show full text]
  • WO 2012/174282 A2 20 December 2012 (20.12.2012) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2012/174282 A2 20 December 2012 (20.12.2012) P O P C T (51) International Patent Classification: David [US/US]; 13539 N . 95th Way, Scottsdale, AZ C12Q 1/68 (2006.01) 85260 (US). (21) International Application Number: (74) Agent: AKHAVAN, Ramin; Caris Science, Inc., 6655 N . PCT/US20 12/0425 19 Macarthur Blvd., Irving, TX 75039 (US). (22) International Filing Date: (81) Designated States (unless otherwise indicated, for every 14 June 2012 (14.06.2012) kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, English (25) Filing Language: CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, Publication Language: English DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, (30) Priority Data: KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, 61/497,895 16 June 201 1 (16.06.201 1) US MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, 61/499,138 20 June 201 1 (20.06.201 1) US OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, 61/501,680 27 June 201 1 (27.06.201 1) u s SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, 61/506,019 8 July 201 1(08.07.201 1) u s TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
    [Show full text]
  • FAM73B (S-12): Sc-240437
    SAN TA C RUZ BI OTEC HNOL OG Y, INC . FAM73B (S-12): sc-240437 BACKGROUND APPLICATIONS Chromosome 9 consists of about 145 million bases and 4% of the human FAM73B (S-12) is recommended for detection of FAM73B of mouse, rat genome and encodes nearly 900 genes. Considered to play a role in gender and human origin by Western Blotting (starting dilution 1:200, dilution determination, deletion of the distal portion of 9p can lead to development of range 1:100-1:1000), immunoprecipitation [1-2 µg per 100-500 µg of total male to female sex reversal, the phenotype of a female with a male X,Y geno - protein (1 ml of cell lysate)], immunofluorescence (starting dilution 1:50, type. Hereditary hemorrhagic telangiectasia, which is characterized by harmful dilution range 1:50-1:500) and solid phase ELISA (starting dilution 1:30, vascular defects, is associated with the chromosome 9 gene encoding Endoglin dilution range 1:30-1:3000); non cross-reactive with FAM73A. protein, ENG. Familial dysautonomia is also associated with chromosome 9 FAM73B (S-12) is also recommended for detection of FAM73B in additional though through the gene IKBKAP. Notably, chromosome 9 encompasses the species, including equine, bovine and porcine. largest interferon family gene cluster. Chromosome 9 is partnered with chro - mosome 22 in the translocation leading to the aberrant production of Bcr-Abl Suitable for use as control antibody for FAM73B siRNA (h): sc-92740, fusion protein often found in leukemias. The FAM73B gene product has been FAM73B siRNA (m): sc-145054, FAM73B shRNA Plasmid (h): sc-92740-SH, provisionally designated FAM73B pending further characterization.
    [Show full text]
  • Supplementary Information – Postema Et Al., the Genetics of Situs Inversus Totalis Without Primary Ciliary Dyskinesia
    1 Supplementary information – Postema et al., The genetics of situs inversus totalis without primary ciliary dyskinesia Table of Contents: Supplementary Methods 2 Supplementary Results 5 Supplementary References 6 Supplementary Tables and Figures Table S1. Subject characteristics 9 Table S2. Inbreeding coefficients per subject 10 Figure S1. Multidimensional scaling to capture overall genomic diversity 11 among the 30 study samples Table S3. Significantly enriched gene-sets under a recessive mutation model 12 Table S4. Broader list of candidate genes, and the sources that led to their 13 inclusion Table S5. Potential recessive and X-linked mutations in the unsolved cases 15 Table S6. Potential mutations in the unsolved cases, dominant model 22 2 1.0 Supplementary Methods 1.1 Participants Fifteen people with radiologically documented SIT, including nine without PCD and six with Kartagener syndrome, and 15 healthy controls matched for age, sex, education and handedness, were recruited from Ghent University Hospital and Middelheim Hospital Antwerp. Details about the recruitment and selection procedure have been described elsewhere (1). Briefly, among the 15 people with radiologically documented SIT, those who had symptoms reminiscent of PCD, or who were formally diagnosed with PCD according to their medical record, were categorized as having Kartagener syndrome. Those who had no reported symptoms or formal diagnosis of PCD were assigned to the non-PCD SIT group. Handedness was assessed using the Edinburgh Handedness Inventory (EHI) (2). Tables 1 and S1 give overviews of the participants and their characteristics. Note that one non-PCD SIT subject reported being forced to switch from left- to right-handedness in childhood, in which case five out of nine of the non-PCD SIT cases are naturally left-handed (Table 1, Table S1).
    [Show full text]
  • The Neuroprotective Role of the GM1 Oligosaccharide, Ii3neu5ac-Gg4, In
    Molecular Neurobiology (2019) 56:6673–6702 https://doi.org/10.1007/s12035-019-1556-8 The Neuroprotective Role of the GM1 Oligosaccharide, 3 II Neu5Ac-Gg4, in Neuroblastoma Cells Elena Chiricozzi1 & Margherita Maggioni1 & Erika di Biase1 & Giulia Lunghi1 & Maria Fazzari1 & Nicoletta Loberto 1 & Maffioli Elisa2 & Francesca Grassi Scalvini2 & Gabriella Tedeschi 2,3 & Sandro Sonnino1 Received: 10 January 2019 /Accepted: 13 March 2019 /Published online: 26 March 2019 # Springer Science+Business Media, LLC, part of Springer Nature 2019 Abstract 3 Recently, we demonstrated that the GM1 oligosaccharide, II Neu5Ac-Gg4 (OligoGM1), administered to cultured murine Neuro2a neuroblastoma cells interacts with the NGF receptor TrkA, leading to the activation of the ERK1/2 downstream pathway and to cell differentiation. To understand how the activation of the TrkA pathway is able to trigger key biochemical signaling, we performed a proteomic analysis on Neuro2a cells treated with 50 μM OligoGM1 for 24 h. Over 3000 proteins were identified. Among these, 324 proteins were exclusively expressed in OligoGM1-treated cells. Interestingly, several proteins expressed only in OligoGM1-treated cells are involved in biochemical mechanisms with a neuroprotective potential, reflecting the GM1 neuroprotective effect. In addition, we found that the exogenous administration of OligoGM1 reduced the cellular oxidative stress in Neuro2a cells and conferred protection against MPTP neurotoxicity. These results confirm and reinforce the idea that the molecular mechanisms underlying the GM1 neurotrophic and neuroprotective effects depend on its oligosaccharide chain, suggesting the activation of a positive signaling starting at plasma membrane level. Keywords GM1 ganglioside . GM1 oligosaccharide chain . TrkA neurotrophin receptor . Plasma membrane signaling . Neuroprotection .
    [Show full text]
  • Content Based Search in Gene Expression Databases and a Meta-Analysis of Host Responses to Infection
    Content Based Search in Gene Expression Databases and a Meta-analysis of Host Responses to Infection A Thesis Submitted to the Faculty of Drexel University by Francis X. Bell in partial fulfillment of the requirements for the degree of Doctor of Philosophy November 2015 c Copyright 2015 Francis X. Bell. All Rights Reserved. ii Acknowledgments I would like to acknowledge and thank my advisor, Dr. Ahmet Sacan. Without his advice, support, and patience I would not have been able to accomplish all that I have. I would also like to thank my committee members and the Biomed Faculty that have guided me. I would like to give a special thanks for the members of the bioinformatics lab, in particular the members of the Sacan lab: Rehman Qureshi, Daisy Heng Yang, April Chunyu Zhao, and Yiqian Zhou. Thank you for creating a pleasant and friendly environment in the lab. I give the members of my family my sincerest gratitude for all that they have done for me. I cannot begin to repay my parents for their sacrifices. I am eternally grateful for everything they have done. The support of my sisters and their encouragement gave me the strength to persevere to the end. iii Table of Contents LIST OF TABLES.......................................................................... vii LIST OF FIGURES ........................................................................ xiv ABSTRACT ................................................................................ xvii 1. A BRIEF INTRODUCTION TO GENE EXPRESSION............................. 1 1.1 Central Dogma of Molecular Biology........................................... 1 1.1.1 Basic Transfers .......................................................... 1 1.1.2 Uncommon Transfers ................................................... 3 1.2 Gene Expression ................................................................. 4 1.2.1 Estimating Gene Expression ............................................ 4 1.2.2 DNA Microarrays ......................................................
    [Show full text]
  • Diagnóstico Molecular Do Transtorno Do Espectro Autista Através Do Sequenciamento Completo De Exoma Molecular Diagnosis Of
    Universidade de São Paulo Tatiana Ferreira de Almeida Diagnóstico molecular do transtorno do espectro autista através do sequenciamento completo de exoma Molecular diagnosis of autism spectrum disorder through whole exome sequencing São Paulo 2018 Universidade de São Paulo Tatiana Ferreira de Almeida Diagnóstico molecular do transtorno do espectro autista através do sequenciamento completo de exoma Molecular diagnosis of autism spectrum disorder through whole exome sequencing Tese apresentada ao Instituto de Biociências da Universidade de São Paulo, para a obtenção de Título de Doutor em Ciências, na Área de Biologia/Genética. Versão corrigida. Orientador(a): Maria Rita dos Santos Passos-Bueno São Paulo ii 2018 Dedico esta tese à ciência, e a todos os seus amantes. O, reason not the need! Our basest beggars Are in the poorest thing superfluous. Allow not nature more than nature needs, Man’s life is cheap as beast’s. Thou art a lady: If only to go warm were gorgeous, Why, nature needs not what thou gorgeous wear’st Which scarcely keeps thee warm. But, for true need- You heavens, give me that patience, patience I need! You see me here, you gods, a poor old man, As full of grief as age; wretched in both.” iii King Lear, William Shakespeare, 1608 Agradecimentos Agradeço em primeiro lugar ao meu grande amor Danilo, sem ele, há 11 anos, essa jornada não teria começado, a vida não teria me surpreendido e eu estaria de volta em casa, com todos os peixinhos do mar, e infeliz pelo resto da minha vida. Agradeço minha família, principalmente minha mãe Flávia e meu pai Airton por sacrificarem com mínimos protestos, as melhores horas que passaríamos juntos para que eu cumprisse meu trabalho.
    [Show full text]
  • Genetics of Abca4-Associated Diseases and Retinitis Pigmentosa
    GENETICS OF ABCA4-ASSOCIATED DISEASES AND RETINITIS PIGMENTOSA Yajing (Angela) Xie Submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy under the Executive Committee of the Graduate School of Arts and Sciences COLUMBIA UNIVERSITY 2016 © 2016 Yajing (Angela) Xie All rights reserved ABSTRACT Genetics of ABCA4-Associated Diseases and Retinitis Pigmentosa Yajing (Angela) Xie Inherited retinal dystrophies encompass a broad group of genetic disorders affecting visual functions in as high as 1 in 3,000 individuals around the world. Common symptoms include loss of central, periphery, or night visions, and in severe cases progression to complete blindness. Syndromic forms also exist involving abnormalities in other parts of the body. Currently, more than 250 genes representing a wide variety of functional roles have been shown to be responsible for the disease phenotypes. Moreover, mutations in the same gene sometimes cause different phenotypes while mutations in multiple genes can give rise to the same clinical subtype, further demonstrating the level of complexity in these disorders. Such genetic heterogeneity has substantially complicated the process of pinpointing precise genetic causes underlying these conditions. The goal of my thesis research is to clarify the genetic causes underlying retinal dystrophies, with a primary focus on phenotypes resembling ABCA4-associated diseases and retinitis pigmentosa in both syndromic and non-syndromic forms. Recent advances in the next-generation sequencing (NGS), the high-throughput, ‘deep’ sequencing technology, have enabled several novel genes to be identified, or found new mutations in known genes. Nevertheless, a substantial fraction of unsolved cases still remain. The primary work in this thesis involves utilizing NGS, particularly whole- exome sequencing, to identify disease-causal mutations in families where at least one parent and affected or unaffected siblings are available.
    [Show full text]
  • Medication Use, Falls and Genetic Variants in an Older Population
    Medication use, falls and genetic variants in an older population Annelies Christine Ham 509950-L-bw-Ham Processed on: 2-5-2017 PDF page: 1 Copyright 2017 © Annelies Christine Ham ISBN: 978-94-028-0651-9 Design and layout: Legatron Electronic Publishing, Rotterdam Cover design: Martijn Reijerse Printing: Ipskamp Printing, Enschede Printing of this thesis was kindly supported by Nederlands Bijwerkingen Fonds and ChipSoft. No part of this thesis may be reproduced, stored in a retrieval system or transmitted in any form or by any means without permission from the author or, when appropriate, from the publishers of the publications. 509950-L-bw-Ham Processed on: 2-5-2017 PDF page: 2 Medication Use, Falls and Genetic Variants in an Older Population Medicatiegebruik, vallen en genetische variatie in een oudere populatie Proefschrift ter verkrijging van de graad van doctor aan de Erasmus Universiteit Rotterdam op gezag van de rector magnificus Prof.dr. H.A.P. Pols en volgens besluit van het College voor Promoties. De openbare verdediging zal plaatsvinden op woensdag 7 juni 2017 15:30 uur door Annelies Christine Ham geboren te Rotterdam 509950-L-bw-Ham Processed on: 2-5-2017 PDF page: 3 Promotiecommissie Promotor: Prof.dr. A.G. Uitterlinden Prof.dr. B.H. Stricker Overige leden: Dr. M.C. Zillikens Prof.dr. R.J. van Marum Prof.dr. P.M.L.A. van den Bemt Copromotor: Dr. N. van der Velde 509950-L-bw-Ham Processed on: 2-5-2017 PDF page: 4 Content Chapter 1 General introduction 7 Chapter 2 Medication-related falls 17 2.1 Medication-related fall incidents
    [Show full text]
  • Genomic Segmental Duplications on the Basis of the T(9;22) Rearrangement in Chronic Myeloid Leukemia
    Oncogene (2010) 29, 2509–2516 & 2010 Macmillan Publishers Limited All rights reserved 0950-9232/10 $32.00 www.nature.com/onc ORIGINAL ARTICLE Genomic segmental duplications on the basis of the t(9;22) rearrangement in chronic myeloid leukemia F Albano1,3, L Anelli1,3, A Zagaria1,3, N Coccaro1, P D’Addabbo2, V Liso1, M Rocchi2,4 and G Specchia1,4 1Department of Hematology, University of Bari, Bari, Italy and 2Department of Genetics and Microbiology, University of Bari, Bari, Italy A crucial role of segmental duplications (SDs) of the (SDs) in triggering constitutional and also tumor human genome has been shown in chromosomal re- chromosomal abnormalities (Sharp et al., 2006; Gibcus arrangements associated with several genomic disorders. et al., 2007; Darai-Ramqvist et al., 2008; Gu et al., 2008; Limited knowledge is yet available on the molecular Mefford and Eichler, 2009). Several rearrangements processes resulting in chromosomal rearrangements in have been described so far to explain the occurrence of tumors. The t(9;22)(q34;q11) rearrangement causing the genomic disorders: recurrent, sharing a common size 50BCR/30ABL gene formation has been detected in more and showing clustering of breakpoints inside the SDs, than 90% of cases with chronic myeloid leukemia (CML). and nonrecurrent rearrangements, involving regions of In 10–18% of patients with CML, genomic deletions different sizes and showing breakpoints scattering in were detected on der(9) chromosome next to translocation large regions (Gu et al., 2008). Most of the recurrent breakpoints. The molecular mechanism triggering the rearrangements result from a nonallelic homologous t(9;22) and deletions on der(9) is still speculative.
    [Show full text]
  • Biological Implications of Differential Expression of Mitochondrial-Shaping Proteins in Parkinson’S Disease
    antioxidants Article Biological Implications of Differential Expression of Mitochondrial-Shaping Proteins in Parkinson’s Disease Sara Rocha 1,2,†, Ana Freitas 1,3,4,†, Sofia C. Guimaraes 1,3, Rui Vitorino 5,6 ID , Miguel Aroso 1,3 and Maria Gomez-Lazaro 1,3,* ID 1 i3S—Instituto de Investigação e Inovação em Saúde, Universidade do Porto, 4200-135 Porto, Portugal; [email protected] (S.R.); [email protected] (A.F.); sofi[email protected] (S.C.G.); [email protected] (M.A.) 2 IBMC—Instituto de Biologia Molecular e Celular, Universidade do Porto, 4200-135 Porto, Portugal 3 INEB—Instituto de Engenharia Biomédica, Universidade do Porto, 4200-135 Porto, Portugal 4 FMUP—Faculdade de Medicina da Universidade do Porto, 4200-319 Porto, Portugal 5 iBiMED, Department of Medical Sciences, University of Aveiro, 3810-193 Aveiro, Portugal; [email protected] 6 Unidade de Investigação Cardiovascular, Departamento de Cirurgia e Fisiologia, Universidade do Porto, 4200-319 Porto, Portugal * Correspondence: [email protected]; Tel.: +351-220-408-815 † These authors contributed equally to this work. Received: 28 November 2017; Accepted: 14 December 2017; Published: 21 December 2017 Abstract: It has long been accepted that mitochondrial function and morphology is affected in Parkinson’s disease, and that mitochondrial function can be directly related to its morphology. So far, mitochondrial morphological alterations studies, in the context of this neurodegenerative disease, have been performed through microscopic methodologies. The goal of the present work is to address if the modifications in the mitochondrial-shaping proteins occurring in this disorder have implications in other cellular pathways, which might constitute important pathways for the disease progression.
    [Show full text]